한글목차

관절내 점성보충 시장은 2024년 47억 6,000만 달러로 평가되며, 2030년에는 76억 8,000만 달러에 달할 것으로 예상되며, 연평균 8.25%의 성장률을 보일 것으로 예상됩니다.

이러한 성장은 특히 고령화 사회에서 골관절염 및 기타 근골격계 질환의 발생률 증가에 기인합니다. 히알루론산 기반 용액을 관절에 주입하는 관절내 점성보충은 수술적 개입을 대체할 수 있는 최소침습적 대안으로 관절 통증을 완화하고 운동성을 향상시켜 줍니다. 이 시장은 제품 개발의 발전과 무릎 골관절염뿐만 아니라 다른 관절로의 적용 확대에 의해 더욱 뒷받침되고 있습니다. 스포츠 관련 부상의 증가와 비수술적 치료법으로의 전환도 수요를 촉진하고 있습니다. 그러나 높은 치료 비용과 일관성 없는 보험 환급 정책이 일부 지역에서는 보급에 걸림돌로 작용하고 있습니다.

시장 촉진요인

고령화 인구 증가

주요 시장 과제

높은 치료비

주요 시장 동향

생체적합성 히알루론산(HA) 유도체

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 관절내 점성보충 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 제품 유형별(1회 주사, 3회 주사, 5회 주사)
  • 용도별(병원, 정형외과 클리닉/ASC)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 관절내 점성보충 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 관절내 점성보충 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 관절내 점성보충 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 관절내 점성보충 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 관절내 점성보충 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병

제13장 PESTEL 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제15장 세계의 관절내 점성보충 시장 : SWOT 분석

제16장 경쟁 구도

• Sanofi SA
• Seikagaku Corporation
• Smith & Nephew PLC.
• Lifecore Biomedical, LLC.
• Fidia Farmaceutici S.p.A
• F.Hoffmann-La Roche Ltd.
• LG Life Sciences Ltd.
• Ferring Pharmaceutical B.V.
• Zimmer Biomet Holdings Inc
• Anika Therapeutics, Inc.

제17장 전략적 제안

제18장 조사 회사 소개 및 면책사항

영문목차

The Viscosupplementation Market was valued at USD 4.76 billion in 2024 and is projected to reach USD 7.68 billion by 2030, growing at a CAGR of 8.25%. This growth is primarily attributed to the increasing incidence of osteoarthritis and other musculoskeletal disorders, particularly among the aging population. Viscosupplementation, which involves injecting hyaluronic acid-based solutions into joints, offers a minimally invasive alternative to surgical interventions, enhancing mobility and reducing joint pain. The market is further supported by advancements in product development and the broadening of applications beyond knee osteoarthritis to other joints. Rising cases of sports-related injuries and the global shift toward non-surgical treatment options have also fueled demand. However, high treatment costs and inconsistent insurance reimbursement policies continue to pose barriers to widespread adoption in some regions.

Key Market Drivers

Rising Aging Population

One of the most influential factors driving growth in the global viscosupplementation market is the rising aging population. According to the United Nations Department of Economic and Social Affairs, the global population aged 60 and above is projected to reach 2.1 billion by 2050, up from 1.2 billion in 2024. This age group is highly susceptible to osteoarthritis (OA), a major condition treated with viscosupplementation. Statistics show that 43% of individuals with OA are aged 65 or older, while 88% are aged 45 or older. The 55-64 age group reports the highest annual incidence of knee OA, positioning them as a key demographic for viscosupplementation therapy. As this segment of the population grows, so does the demand for effective, non-surgical joint treatments to improve mobility and quality of life. This demographic trend supports the long-term expansion of the viscosupplementation market.

Key Market Challenges

High Treatment Cost

The elevated cost of viscosupplementation treatments presents a major challenge for market expansion. These treatments often require multiple injections over time, especially for chronic conditions like osteoarthritis, leading to recurring expenses. This becomes a financial burden for patients lacking sufficient insurance coverage and creates reimbursement hurdles for healthcare providers. In some healthcare systems, limited insurance policies or delays in reimbursement further deter the adoption of these therapies. The high cost may prompt patients to pursue more affordable alternatives such as medications or physical therapy. To mitigate this issue, the market must focus on enhancing cost-efficiency through pricing strategies, improved insurance coverage, and patient education regarding the long-term benefits of viscosupplementation over other management options for joint pain.

Key Market Trends

Biocompatible Hyaluronic Acid (HA) Derivatives

A notable trend in the Viscosupplementation Market is the increasing development and use of biocompatible hyaluronic acid (HA) derivatives. These derivatives are engineered to replicate the properties of natural HA more closely, offering longer-lasting joint lubrication and improved pain relief. By minimizing injection frequency and maximizing therapeutic outcomes, these products enhance patient compliance and comfort. Additionally, their improved safety profile-due to a lower likelihood of adverse reactions-makes them more favorable for long-term use. Patients benefit from extended relief and reduced joint inflammation, resulting in better mobility and higher satisfaction. Manufacturers are investing in research to develop advanced HA derivatives that offer more effective, durable, and convenient treatment options. This trend is expected to reshape osteoarthritis care by providing innovative solutions that improve patient outcomes and treatment experiences.

Key Market Players

• Sanofi SA
• Seikagaku Corporation
• Smith & Nephew PLC.
• Lifecore Biomedical, LLC.
• Fidia Farmaceutici S.p.A
• F. Hoffmann-La Roche Ltd.
• LG Life Sciences Ltd.
• Ferring Pharmaceutical B.V.
• Zimmer Biomet Holdings Inc
• Anika Therapeutics, Inc.

Report Scope:

In this report, the Global Viscosupplementation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Viscosupplementation Market, By Product Type:

• Single Injection
• Three Injection
• Five Injection

Viscosupplementation Market, By End User:

• Hospitals
• Orthopedic Clinics/ASCs

Viscosupplementation Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Viscosupplementation Market.

Available Customizations:

Global Viscosupplementation market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Viscosupplementation Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Single Injection, Three Injection, Five Injection)
  • 5.2.2. By End Use (Hospitals, Orthopedic Clinics/ASCs)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Viscosupplementation Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Viscosupplementation Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By End Use
  • 6.3.2. Canada Viscosupplementation Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By End Use
  • 6.3.3. Mexico Viscosupplementation Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By End Use

7. Europe Viscosupplementation Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Viscosupplementation Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By End Use
  • 7.3.2. United Kingdom Viscosupplementation Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By End Use
  • 7.3.3. Italy Viscosupplementation Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By End Use
  • 7.3.4. France Viscosupplementation Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Viscosupplementation Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By End Use

8. Asia-Pacific Viscosupplementation Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Viscosupplementation Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Viscosupplementation Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By End Use
  • 8.3.3. Japan Viscosupplementation Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By End Use
  • 8.3.4. South Korea Viscosupplementation Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Viscosupplementation Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By End Use

9. South America Viscosupplementation Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Viscosupplementation Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By End Use
  • 9.3.2. Argentina Viscosupplementation Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By End Use
  • 9.3.3. Colombia Viscosupplementation Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By End Use

10. Middle East and Africa Viscosupplementation Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Viscosupplementation Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By End Use
  • 10.3.2. Saudi Arabia Viscosupplementation Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By End Use
  • 10.3.3. UAE Viscosupplementation Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Global Viscosupplementation Market: SWOT Analysis

16. Competitive Landscape

• 16.1. Sanofi SA
  • 16.1.1. Business Overview
  • 16.1.2. Product & Service Offerings
  • 16.1.3. Recent Developments
  • 16.1.4. Financials (If Listed)
  • 16.1.5. Key Personnel
  • 16.1.6. SWOT Analysis
• 16.2. Seikagaku Corporation
• 16.3. Smith & Nephew PLC.
• 16.4. Lifecore Biomedical, LLC.
• 16.5. Fidia Farmaceutici S.p.A
• 16.6. F.Hoffmann-La Roche Ltd.
• 16.7. LG Life Sciences Ltd.
• 16.8. Ferring Pharmaceutical B.V.
• 16.9. Zimmer Biomet Holdings Inc
• 16.10.Anika Therapeutics, Inc.

17. Strategic Recommendations

18. About Us & Disclaimer